Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1720
http://purl.obolibrary.org/obo/NCIT_C1720
|
|---|---|
| Preferred Name | Alpha Galactosylceramide |
| Definitions |
A potent alpha galactosylceramide modified from marine-sponge that stimulates the immune system to exhibit antitumor activity.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A potent alpha galactosylceramide modified from marine-sponge that stimulates the immune system to exhibit antitumor activity. |
|---|---|
| prefLabel | Alpha Galactosylceramide
|
| label | Alpha Galactosylceramide
|
| CHEBI_ID | CHEBI:466659
|
| PDQ_Closed_Trial_Search_ID | 43562
|
| code | C1720
|
| prefixIRI | NCIT:C1720
|
| in_subset |
See more
See less
|
| Display_Name | Alpha Galactosylceramide
|
| Preferred_Name | Alpha Galactosylceramide
|
| FDA_UNII_Code | WX671898JF
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Alpha Galactosylceramide
|
| CAS_Registry | 158021-47-7
|
| NCI_Drug_Dictionary_ID | 43562
|
| Legacy Concept Name | KRN7000
|
| type | |
| ALT_DEFINITION | A drug being studied in the treatment of cancer. It is a biological response modifier that belongs to the family of drugs called glycosphingolipids or agelasphins.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 43562
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0534775
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |